Andrew Lewis

Spatial cardiology; Our research group at Oxford develops and applies advanced imaging techniques across various spatial scales, from subcellular to whole-heart, to better understand cardiovascular disease mechanisms, identify new therapeutic targets, and enhance early detection of treatment effects in experimental medicine trials. By integrating human cells, tissue samples, and non-invasive imaging of research and trial participants and patients, we aim to maximise the translational potential and mechanistic insights of our work. Current projects focus on metabolic and immunological pathways in heart failure, exploiting state-of-the-art spatial profiling techniques.

[2026] Multimodality Diagnosis and Management of Carcinoid Heart Disease: Outcomes and Long-Term Follow-Up. Johnson N. et al, (2026), JACC Case Rep [2026] Scoping review of preclinical and clinical studies on the role of HMGB1 in heart disease. Mao S-H. et al, (2026), NPJ Cardiovasc Health, 3 [2026] Clinical Applications of Artificial Intelligence in Cardiovascular Imaging: Where Do We Stand? Singhal AA. et al, (2026), Life (Basel), 16 [2026] Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction. Zhang K. et al, (2026), Science, 391 [2026] First-in-Human Study of the Carbohydrate Nanoparticle 64Cu-Macrin. O'Shea A. et al, (2026), J Nucl Med, 67, 449 - 455